How to Get Low-Dose Naltrexone in Louisiana

Louisiana Allows Telehealth Prescribing of Low-Dose Naltrexone

Any Louisiana resident with internet access can consult a licensed telehealth provider for an LDN prescription without leaving home. The Louisiana State Board of Medical Examiners permits synchronous audio-video telemedicine encounters for prescribing, and naltrexone carries no DEA scheduling restrictions that would block remote prescribing [1].

Louisiana updated its telemedicine practice rules under La. R.S. 37:1271.1, which maintained expanded telehealth access established during the COVID-19 public health emergency. A provider licensed in Louisiana (or holding a multistate compact license recognized by the state) can evaluate a patient, review labs, and transmit a prescription to a compounding pharmacy in a single visit. The prescriber must establish a valid patient-provider relationship, but Louisiana does not require an in-person visit before initiating naltrexone therapy.

Telehealth platforms specializing in LDN typically charge $99 to $175 for an initial consultation, with follow-ups running $50 to $99. Some bundle the pharmacy cost into a monthly subscription. Because LDN is prescribed off-label for conditions like fibromyalgia and autoimmune disease, the provider must document the clinical rationale, but no prior authorization is needed for cash-pay compounding [2].

Who Can Prescribe LDN in Louisiana

LDN does not require a specialist. Any provider with prescriptive authority in Louisiana can write for compounded naltrexone at low doses.

That includes physicians (MD and DO), nurse practitioners (APRNs with full practice authority), and physician assistants operating under collaborative practice agreements. Louisiana granted APRNs independent practice authority effective January 1, 2021, meaning NPs can prescribe LDN without physician oversight after completing the required 2,080 supervised clinical hours [3].

Rheumatologists, pain management physicians, functional medicine practitioners, and primary care providers are the most common prescribers. However, no board certification in a specific specialty is required. The prescriber documents the off-label rationale (typically citing inflammatory or pain-related indications), writes for a specific dose (commonly starting at 1.5 mg and titrating to 4.5 mg over 4 to 8 weeks), and sends the prescription to a compounding pharmacy.

How 503A Compounding Pharmacies Work in Louisiana

LDN is not available as a manufactured product at standard retail pharmacies. You need a 503A compounding pharmacy.

Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies that prepare medications based on individual patient prescriptions [4]. Louisiana's Board of Pharmacy licenses in-state compounding pharmacies and permits out-of-state 503A pharmacies to ship compounded medications to Louisiana patients, provided those pharmacies hold a valid nonresident pharmacy license issued by the Louisiana Board.

The typical process: your prescriber sends a prescription specifying naltrexone at the desired dose (e.g., "naltrexone 4.5 mg oral capsule, #30, take one capsule at bedtime"). The compounding pharmacy verifies the prescription, compounds the capsules from bulk naltrexone powder, performs quality testing, and ships directly to the patient. Most pharmacies ship via USPS Priority Mail or FedEx Ground.

Louisiana-based compounding pharmacies that fill LDN prescriptions include those operating in Baton Rouge, New Orleans, and Shreveport. Several national 503A pharmacies also hold Louisiana nonresident licenses. Expect to pay $30 to $60 per month for a 30-day supply, depending on the pharmacy and dose.

Labs Required Before Starting LDN

Most prescribers require baseline labs before initiating low-dose naltrexone to rule out liver dysfunction and establish a clinical baseline.

The standard pre-LDN panel includes a comprehensive metabolic panel (CMP) with particular attention to hepatic transaminases (ALT and AST), a complete blood count (CBC), and in some cases inflammatory markers like C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR). Naltrexone at full doses (50 mg) carries an FDA black-box warning for hepatotoxicity, though this concern is largely theoretical at LDN doses of 1.5 to 4.5 mg [5].

A 2014 retrospective review of 215 patients taking LDN at doses between 1 and 5 mg found no clinically significant elevations in liver enzymes over 12 months of therapy [6]. Younger et al. in their pilot trial of LDN for fibromyalgia (N=10) reported no hepatic adverse events at 4.5 mg daily over 8 weeks [7]. Still, most providers recheck liver function at 8 to 12 weeks after initiation and then annually.

If you already have labs from the past 60 to 90 days, many telehealth providers will accept those results. Otherwise, you can obtain labs at any Quest Diagnostics, Labcorp, or hospital outpatient lab in Louisiana. Walk-in labs are available in every major Louisiana metro area without a separate physician order if you use a direct-to-consumer lab service.

Louisiana Medicaid Does Not Cover LDN

Louisiana Medicaid does not reimburse for low-dose naltrexone prescribed off-label for inflammation, fibromyalgia, or autoimmune conditions. This is consistent with most state Medicaid programs.

Naltrexone at its FDA-approved 50 mg dose for opioid use disorder and alcohol dependence is covered under Louisiana Medicaid's preferred drug list [8]. But compounded formulations at non-standard doses for off-label indications fall outside formulary coverage. Private insurers in Louisiana (Blue Cross Blue Shield of Louisiana, Aetna, UnitedHealthcare) similarly do not cover compounded LDN, though they may cover the 50 mg tablet for approved indications.

The practical result: LDN is a cash-pay medication for nearly all Louisiana patients. At $30 to $60 per month, it remains one of the least expensive prescription options for chronic pain and autoimmune support. Some patients use health savings accounts (HSAs) or flexible spending accounts (FSAs) to pay for both the telehealth consultation and the compounded medication, as both qualify as eligible medical expenses.

The Clinical Evidence Behind LDN

Younger et al. published the first controlled trial of LDN for fibromyalgia in 2009, demonstrating a 30% reduction in pain symptoms versus placebo in a crossover design (N=10, P=0.016) [7]. A subsequent larger trial by Younger et al. in 2013 (N=31) confirmed these findings, showing significantly greater pain reduction during LDN treatment compared to placebo, with effect sizes exceeding 0.5 [9].

The proposed mechanism involves transient opioid receptor blockade at low doses, which upregulates endogenous opioid production and modulates microglial activation in the central nervous system. Toll-like receptor 4 (TLR4) antagonism appears to reduce neuroinflammation independent of the opioid pathway [10].

Beyond fibromyalgia, published evidence supports LDN use in Crohn's disease (Smith et al., 2007, N=17 to 89% response rate at 4.5 mg) [11], multiple sclerosis (Gironi et al., 2008, open-label safety data) [12], and complex regional pain syndrome. A 2020 systematic review in Biomedicines identified 89 published studies on LDN across pain, autoimmune, and oncologic indications, concluding that LDN demonstrates a favorable safety profile with promising efficacy signals warranting larger randomized trials [13].

The Endocrine Society and American College of Rheumatology have not issued formal position statements on LDN. Prescribing remains off-label, guided by the growing but still preliminary evidence base.

Step-by-Step Process to Get LDN in Louisiana

Getting LDN in Louisiana takes three steps, and most patients complete them within two weeks.

Step 1: Consultation. Schedule a telehealth or in-person visit with a provider who prescribes LDN. Bring documentation of your diagnosis (fibromyalgia, Hashimoto's thyroiditis, rheumatoid arthritis, chronic pain, or other qualifying condition) and recent labs if available. The provider will review your medical history, confirm no contraindications (current opioid use is a primary exclusion), and discuss dosing.

Step 2: Prescription. The provider transmits the prescription electronically to a 503A compounding pharmacy. You can request a specific pharmacy or use one the provider recommends. Confirm the pharmacy holds a Louisiana license (resident or nonresident) before filling.

Step 3: Fulfillment and delivery. The pharmacy compounds your prescription, typically within 3 to 5 business days, then ships to your Louisiana address. Total time from consultation to medication in hand: 5 to 10 business days for most patients. Some pharmacies offer expedited shipping for an additional $10 to $20.

Contraindications to confirm before starting: active opioid use (LDN will precipitate withdrawal), acute hepatitis or liver failure, and known hypersensitivity to naltrexone. Patients must be opioid-free for a minimum of 7 to 14 days before initiating LDN [5].

Transferring an Existing LDN Prescription to Louisiana

If you already take LDN and are relocating to Louisiana, your existing prescription can follow you with minimal disruption.

Louisiana Board of Pharmacy regulations permit prescription transfers between pharmacies, including from out-of-state compounding pharmacies to Louisiana-licensed facilities. The simplest route: contact your new Louisiana pharmacy, provide your current pharmacy's information, and authorize the transfer. Alternatively, your prescribing provider can send a new prescription directly to a Louisiana pharmacy.

If your prescriber is not licensed in Louisiana, you will need a new provider. Telehealth platforms make this transition straightforward, as the new provider can review your records, confirm your stable dose, and issue a new prescription within a single visit. Most will accept chart notes from your prior provider documenting your treatment history and response.

Patients already on a stable LDN dose typically do not need new baseline labs for a prescription transfer, though the new provider may request updated labs at their discretion.

What to Expect After Starting LDN

The most common early side effects are vivid dreams and mild sleep disruption during the first 1 to 2 weeks. These typically resolve without intervention.

Standard titration begins at 1.5 mg nightly for 2 weeks, increases to 3 mg for 2 weeks, then reaches the target dose of 4.5 mg. Some providers start at 0.5 mg or 1 mg for patients with known medication sensitivities. Clinical response typically becomes apparent between weeks 4 and 12. Younger et al. observed peak symptom improvement at week 8 of continuous dosing [7].

Follow-up visits are generally scheduled at 4 to 6 weeks and then every 3 months during the first year. Labs (CMP with hepatic panel) are rechecked at the 8 to 12 week mark. If liver enzymes remain within normal limits and symptoms improve, therapy continues indefinitely for most patients.